로딩 중…
지수 로딩 중…
SunBio,Inc.
067370· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,220-2.30%
2026-06-19
Price Chart
SunBio,Inc.-1.77%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 88.04B KRW |
| Revenue | 11.94B KRW |
| Net Income | 1.79B KRW |
| Total Assets | 62.27B KRW |
| Net Assets | 29.19B KRW |
| Employees | 23 |
| Value | |
| P/E | 49.15x |
| P/B | 3.02x |
| P/S | 7.37x |
| EV/EBITDA | 82.34x |
| FCF Yield | 0.58% |
| Profitability | |
| ROE | 6.14% |
| ROA | 2.88% |
| Op. Margin | 11.52% |
| Revenue Growth | -57.37% |
| Earnings Growth | -48.31% |
| Financial Health | |
| Debt Ratio | 213.32% |
| Total Debt | 30.61B KRW |
| FCF | 515.0M KRW |
| Cash | 5.42B KRW |
| Current Ratio | 0.41x |
| Net Debt/EBITDA | 18.32x |
| Performance | |
| 1Y Return | -1.77% |
| 1M Return | 10.40% |
| From 52W High | -15.06% |
| 1Y MDD | -38.19% |
| Trading | |
| Volume | 504,176 shares |
| Foreign Own. | 0.45% |
| Per Share | |
| EPS | 203 KRW |
| BPS | 2,400 KRW |
Company Info
Seonbio, established in 1997 and listed on KOSDAQ in 2022 as a technology growth company, specializes in the research, development, production, and sales of biopharmaceuticals, medical devices, and PEG derivatives. Utilizing its PEGylation technology, the company has commercialized various biopharmaceuticals, biosimilar drugs, and medical devices. Its neutropenia treatment Pegfilgrastim biosimilar is sold in the EU, Canada, Australia, and India, while the dry mouth treatment MucoPEG received US FDA sales approval in 2019.